Daina Graybosch
Stock Analyst at Leerink Partners
(0.85)
# 3,909
Out of 4,996 analysts
103
Total ratings
38.36%
Success rate
-10.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.78 | +12.36% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.80 | +151.29% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.96 | +257.14% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $20.95 | -42.72% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $78.56 | +51.48% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.59 | +25.79% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.42 | +269.00% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $79.69 | -51.06% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $58.50 | -23.08% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.51 | +2,649.95% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $1.00 | +900.00% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $12.84 | +195.95% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.82 | +109.23% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $98.08 | +128.38% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.04 | +1,370.59% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $2.07 | +721.26% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.40 | +542.86% | 4 | Feb 25, 2022 |
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.78
Upside: +12.36%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.80
Upside: +151.29%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.96
Upside: +257.14%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $20.95
Upside: -42.72%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $78.56
Upside: +51.48%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.59
Upside: +25.79%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.42
Upside: +269.00%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $79.69
Upside: -51.06%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $58.50
Upside: -23.08%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.51
Upside: +2,649.95%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.00
Upside: +900.00%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $12.84
Upside: +195.95%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.82
Upside: +109.23%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $98.08
Upside: +128.38%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.04
Upside: +1,370.59%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $2.07
Upside: +721.26%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.40
Upside: +542.86%